Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical is facing some short term challenges with the Nucynta franchise and uncertainty surrounding potential Belbuca generic competition, leading to a recent decrease in revenue guidance. However, the company's focus on responsible pain management and expansion into the ADHD market with Jornay PM and Azstarys show promise for long term growth. The recent growth of Jornay PM, with a mid-60% gross-to-net spread, and expanded ADHD-focused sales force also bodes well for future success. With a diverse portfolio and strong growth prospects, Collegium Pharmaceutical has a positive outlook for the future.

Bears say

Collegium Pharmaceutical is a biopharmaceutical company with a diversified portfolio of products focused on ADHD and pain treatment. Despite a strong initial quarter for Azstarys, concerns about generic competition for its pain management products and reliance on third-party suppliers may hinder the company's profitability in the future. However, its strong cash position and potential for business development opportunities could present some opportunities for growth and potential expansion into rare disease markets.

Collegium Pharmaceutical (COLL) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 5 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Aug 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.